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AbstrACt
Objective To systematically perform a meta-analysis of 
the association between different comorbid conditions 
on safety (short-term outcomes) and effectiveness (long-
term outcomes) in patients undergoing hip and knee 
replacement surgery.
Design Systematic review and meta-analysis.
Methods Medline, Embase and CINAHL Plus were 
searched up to May 2017. We included all studies that 
reported data to allow the calculation of a pooled OR for 
the impact of 11 comorbid conditions on 10 outcomes 
(including surgical complications, readmissions, mortality, 
function, health-related quality of life, pain and revision 
surgery). The quality of included studies was assessed 
using a modified Newcastle-Ottawa Scale. Continuous 
outcomes were converted to ORs using the Hasselblad 
and Hedges approach. Results were combined using a 
random-effects meta-analysis.
Outcomes The primary outcome was the adjusted OR for 
the impact of each 11 comorbid condition on each of the 
10 outcomes compared with patients without the comorbid 
condition. Where the adjusted OR was not available the 
secondary outcome was the crude OR.
results 70 studies were included with 16 (23%) reporting 
on at least 100 000 patients and 9 (13%) were of high 
quality. We found that comorbidities increased the short-
term risk of hospital readmissions (8 of 11 conditions) 
and mortality (8 of 11 conditions). The impact on surgical 
complications was inconsistent across comorbid 
conditions. In the long term, comorbid conditions increased 
the risk of revision surgery (6 of 11 conditions) and long-
term mortality (7 of 11 conditions). The long-term impact 
on function, quality of life and pain varied across comorbid 
conditions.
Conclusions This systematic review shows that 
comorbidities predominantly have an impact on the safety 
of hip and knee replacement surgery but little impact on 
its effectiveness. There is a need for high-quality studies 
also considering the severity of comorbid conditions.
IntrODuCtIOn
Hip and knee replacement surgery, the 
surgical replacement of a joint, is one 
of the most successful and cost-effective 
interventions in medicine.1 It offers consid-
erable improvement in function and quality 
of life.2 It is expected that the demand for 
hip and knee replacement will increase as 
the prevalence of hip and knee osteoarthritis 
rises due to increases in life expectancy.3 
There has been increasing interest in iden-
tifying the risk factors for poor outcomes of 
elective joint replacement to be able to opti-
mise patients and improve outcomes. Previous 
research has reported variation in the use 
of hip and knee replacement according to 
socioeconomic status,4 sex,5 insurance status,6 
ethnicity7 and geography.8 This variation may 
be explained in part by the lack of consensus 
among clinicians about the clinical indica-
tions for joint replacement surgery.9
Comorbid conditions, conditions that are 
present in addition to the index condition 
but are unrelated to the latter, are on the rise 
around the world as more people are living 
with multiple morbidities. In a large US study 
using administrative data, 83.7% patients who 
had undergone hip or knee replacement had 
strengths and limitations of this study
 ► This study went beyond published reviews by an-
alysing the relative impact of individual comorbid 
conditions on multiple outcomes that relate to safe-
ty and effectiveness of hip and knee replacement 
surgery.
 ► Further to previous studies, to allow for meta-analy-
sis of all outcomes, continuous outcomes were con-
verted to the corresponding OR using the Hasselblad 
and Hedges approach.
 ► The search was limited to include specific comor-
bidities and outcomes so studies may have been 
missed.
 ► To enable a meta-analysis of the multiple conditions 
and outcomes, comorbid conditions and outcomes 
were grouped together and may have compromised 
the validity of the conclusions.
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at least one comorbid condition.10 This is higher than in 
the general population where in 2012 only 49.8% of US 
adults had at least one comorbid condition.11 As the prev-
alence of people living with multiple morbidities increases 
with age, it is expected that the number of patients under-
going elective hip and knee replacement with at least one 
comorbid condition will increase.12
There have been a number of studies reporting the 
impact of comorbidity on outcomes after hip and knee 
replacement.13–15 There is little evidence, however, to 
which extent different individual comorbid conditions 
affect a variety of outcomes that relate not just to the safety 
of the surgery but also long-term outcomes such as quality 
of life after hip and knee replacement surgery. Previous 
systematic reviews on comorbid conditions and outcomes 
of hip and knee replacement have typically focused on 
individual comorbidities,16 specific outcomes,17 process 
measures and cost,18 short-term outcomes following hip 
and knee replacement or the overall impact of composite 
comorbidity indices on outcomes.14
This study provides evidence of the impact of different 
individual comorbid conditions on a wide range of surgical 
outcomes, including short-term outcomes related to the 
‘safety’ of the surgery and long-term outcomes related to 
the ‘effectiveness’ of the surgery.
The aim of this systematic review and meta-analysis was 
to synthesise the literature on the impact of different indi-
vidual comorbid conditions on short-term and long-term 
outcomes of hip and knee replacement surgery.
MethODs
Patient and public involvement
This systematic review forms part of a wider piece of work 
investigating the access to and outcomes of hip and knee 
replacement surgery for patients with comorbidities. The 
protocol, including the systematic review, was reviewed 
by patient representatives on the National Institute for 
Health Research (NIHR) Collaboration for Leadership 
in Applied Health Research and Care (CLAHRC) North 
Thames Patient and Public Involvement committee. 
Their comments and feedback were incorporated in the 
protocol.
Literature search
A search of Medline, Embase and CINAHL Plus was 
conducted up to 31 May 2017 to identify studies written 
in English. Limitations were not placed on date. Search 
terms for hip and knee replacement were combined with 
search terms for health outcomes and search terms for 11 
common comorbid conditions: heart disease, high blood 
pressure, stroke, leg pain due to poor circulation, lung 
disease, diabetes, kidney disease, diseases of the nervous 
system, liver disease, cancer and depression (see online 
supplementary information 1). The conditions were 
selected because they are the comorbid conditions that 
are routinely captured in the national Patient-Reported 
Outcome Measures (PROMs) programme for patients 
undergoing elective surgery in the English National 
Health Service and were considered relevant comorbid-
ities in terms of outcome prediction.19 Where possible 
MeSH or index terms were used. All the titles, selected 
abstracts and full-text articles were reviewed for eligibility 
by two reviewers (BP, AA). Data extraction was conducted 
by BP and checked by AH. Any disagreements were 
resolved by two reviewers (JvdM, AH). The reference lists 
of existing systematic reviews and included studies were 
also checked for additional eligible articles.
eligibility criteria and data extraction
We included published full-text observational (either 
prospective or retrospective) studies in the English 
language that compared the outcomes of hip or knee 
replacement in patients with and without any of the 11 
comorbid conditions. Studies were ineligible if they used 
a summary comorbidity index (eg, Charlson Comorbidity 
Index) or a single count of comorbidities because the 
aim of our study was to understand the impact of indi-
vidual comorbid conditions. Studies, including other 
joint replacements, were only eligible if hip and/or knee 
replacement represented at least 90% of participants or 
if results were reported separately. Small studies, those 
with fewer than 100 participants, were excluded because 
hip and knee replacement are common procedures and 
the selected comorbid conditions are relatively common. 
Studies were ineligible if they failed to include at least 
one of the following outcomes: surgical complications, 
mortality, function, pain, health-related quality of life, 
hospital readmission and revision surgery.
Information on the study design, population and 
measures of association was extracted for eligible studies. 
Data were extracted on the participants (type of surgery), 
source of study data, the specific condition and the defi-
nition of the outcome for each reported association 
between a comorbid condition and outcome in a study 
(see online supplementary information 2). In addition, 
data were also extracted on the measure of association 
and its uncertainty and, for adjusted measures, the vari-
ables used in the adjusted analysis. Where possible, data 
on counts or means were used to calculate measures of 
association that had not been reported in the original 
study. Studies that indicated the statistical significance or 
otherwise of an association without reporting a quanti-
tative metric were also recorded. Data were verified by a 
third reviewer (JvdM).
Ten categories of outcome were defined. Five short-
term outcomes, those occurring closest to 3 months after 
surgery, were: surgical complications, occurrence of 
venous thromboembolism (VTE), surgical site infections, 
readmission to hospital and mortality. Surgical complica-
tions were defined as the presence of any surgical compli-
cation as reported in a study. Two commonly reported 
surgical complications, VTE and infection, were also 
examined separately. Five long-term outcomes closest 
to 1 year postoperatively were: measures of hip or knee 
function, patient-reported quality of life, pain, revision 
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surgery and mortality. We defined short-term outcomes 
as maximum 3 months and long-term outcomes as closest 
to 1 year after surgery because this reflected the defini-
tions of outcomes used in the included studies and our 
judgement of events that reflect safety and effectiveness. 
For function and quality of life, they were only eligible 
for inclusion if analyses incorporated adjustment for 
preoperative scores or if similarity of preoperative scores 
was demonstrated. This was to ensure that the outcome 
captures the impact of surgery rather than any preopera-
tive difference in score.
Quality assessment
The internal and external validity of the studies was 
appraised using the Newcastle-Ottawa Scale (NOS)20 
that was modified to meet the requirements of this study 
(see box 1). Two reviewers (BP, AH) examined three 
items: patient selection, comparability of exposure and 
reference groups, and assessment of outcomes. For the 
comparability between the two groups, we focused on 
the following variables that previous studies have identi-
fied as predictors of various outcomes of hip and knee 
replacement surgery: age, sex, socioeconomic status and 
ethnicity. We added an extra item to assess the compara-
bility of the cohorts on the basis of whether the cohort 
of patients were drawn from multiple centres or a single 
centre and whether the data sources were from specialist 
arthroplasty databases. The total possible score was 13. A 
study with a score of 11 or greater was considered high 
quality (see online supplementary information 3). This 
was to ensure we only included the highest quality studies 
and excluded those where there were concerns with 
cohort selection, confounding and outcome assessment.
Quantitative data synthesis and meta-analysis
An approach to data synthesis was chosen which allowed 
for a meta-analysis across multiple outcomes and condi-
tions. This meta-synthesis approach has been used by a 
previous systematic review.21 The first stage of data synthesis 
involved selecting each study’s measures of association to 
be included in the meta-analyses for each of the possible 
combinations of comorbid condition and outcome. Indi-
vidual studies might have multiple measures for different 
combinations, for example, studies reporting multiple 
outcomes or different comorbid conditions. Studies 
might also have multiple measures for the same combi-
nation, for example, unadjusted and adjusted measures, 
measures for controlled and uncontrolled diabetes, or 
measures for hip and knee replacement surgery. Separate 
measures for hip and knee replacement were included 
box 1 study quality appraisal using a modified 
newcastle-Ottawa scale*
Patient selection
1. Was the cohort of patients undergoing hip or knee replacement sur-
gery with comorbid conditions representative?
2. Was the reference cohort for patients without comorbid conditions 
drawn from the same community?
3. Was the presence of comorbid conditions adequately verified? 
(Yes=secure record or structured interview/self-report.)
4. Did the study demonstrate that the outcome of interest was not 
present at the start of the study?
5. Was the cohort or patients drawn from multiple communities?
Comparability
1.  Did the study control for age and sex?
2.  Did the study control for socioeconomic status and ethnicity?
Outcome assessment
1.  Was the outcome of interest clearly defined? (Yes=study specific/
self-report, joint registry, No=administrative data.)
2.  Was follow-up long enough for outcomes to occur? 
(Yes=short term minimum 30 days, long term minimum 6 months.)
3.  Was follow-up adequate? (Yes=completed follow up >90%.)
*Studies were graded on an ordinal scoring scale with higher scores indicating 
studies of higher quality. A study could be awarded a maximum of one point for 
each numbered item except comparability items and the first item in outcome 
assessment, which could be awarded a maximum of two points for each 
numbered item.
Table 1 Mapping of comorbid conditions
Comorbid 
condition
No of 
studies
Included comorbid 
conditions
Cancer 9 All cancers but if reported 
separately cancer chosen in 
preference to metastasis.
Depression 12 All diagnoses of depression
Diabetes 41 Type 2 diabetes in preference 
to type 1 diabetes. 
Controlled diabetes in 
preference to uncontrolled 
diabetes. Diabetes without 
complications in preference to 
diabetes with complications.
Diseases of the 
nervous system
6 Alzheimer’s disease, 
Parkinson’s disease, 
dementia.
Heart disease 21 Heart disease but if reported 
separately coronary heart 
disease, coronary artery 
disease or heart failure was 
chosen.
High blood 
pressure
13 High blood pressure.
Kidney disease 19 Renal disease but if reported 
separately chosen chronic 
kidney disease, chronic renal 
disease or renal failure.
Liver disease 7 Liver disease but if reported 
separately cirrhosis chosen.
Lung disease 18 Lung disease but if reported 
separately chronic obstructive 
pulmonary disorder chosen.
Poor circulation 7 Peripheral vascular disease.
Stroke 12 Stroke or cerebrovascular 
disease.
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in a combination’s meta-analysis because they comprised 
different groups of participants. For other multiple 
measures, a single measure was selected for inclusion in 
a meta-analysis using the following criteria: adjusted over 
unadjusted measures, closer matching or more common 
subcategories of comorbid conditions for inexact 
mapping to the 11 selected conditions (see table 1), and 
closer matching to the timing (3 or 12 months) and defi-
nition of outcomes.
Most of the studies reported outcomes as ORs or it was 
possible to derive an OR. For studies reporting contin-
uous outcomes the difference between means divided 
by the pooled SD (standardised mean difference) was 
converted to the corresponding OR using the Hasselblad 
and Hedges approach.22 If higher scores represented a 
good outcome then reciprocal values were used to ensure 
that ORs greater than 1 represented higher odds of a 
poor outcome. Where zero events precluded the calcu-
lation of an OR, each cell in the contingency table was 
inflated by adding 0.523 to allow calculation of an OR.
We estimated the pooled OR for each combination of 
comorbid condition and outcome comprising two or more 
measures of association. ORs were computed such that a 
result greater than 1 indicates a higher odds of a worse 
outcome in patients with a specified comorbid conditions 
compared with patients without. We used a random-ef-
fects model as results were drawn from different popu-
lations.24 Pooled ORs by condition were plotted for each 
outcome. A sensitivity analysis was performed to assess 
the impact of the quality of the studies on the outcomes 
by comparing higher quality studies with studies of lower 
quality. The risk of publication bias was assessed using the 
graphical assessment of the funnel plot23 on outcomes 
which were reported on by a greater than six studies. All 
statistical analyses were carried out using STATA V.14.
resuLts
selected studies
Full search results are represented in figure 1. Of the 
18 644 studies identified in the search, we included 70 
studies,25–94 which produced 314 results for individual 
comorbid conditions and outcomes of hip and knee 
replacement surgery. The 70 studies had a range of 
patients sample sizes from 122 to 8 379 490. Sixteen (23%) 
studies had at least 100 000 patients. Twenty-six (37%) 
studies reported combined hip and knee arthroplasties, 
12 (17%) studies reported on hip arthroplasties only, 24 
(34%) studies on knee arthroplasties and 9 (13%) studies 
reported hip and knee arthroplasties separately. Forty 
(70%) studies reported outcomes after primary hip or 
knee replacement. The 70 studies came from 13 different 
countries with 37 (53%) coming from the USA. They 
were published between 1984 and 2017.
Overall, 43 (61%) studies only looked at single 
comorbid conditions and 35 (50%) only looked at single 
Figure 1 Flow chart.
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outcomes. Sixty (86%) studies investigated the associa-
tion between comorbid conditions and surgical compli-
cations (including VTE and surgical site infections), and 
only 5 (7%) quality of life. The comorbid condition that 
was most frequently studied was diabetes (41 studies), 
followed by heart disease (21 studies) and kidney disease 
(19 studies) (see table 1). The least frequently studied 
comorbid condition was diseases of the nervous system 
(six studies).
The median NOS score, the measure of study quality, 
was 10 (6–13). Of the 70, nine (13%) studies met our 
predefined criteria for high quality of scores of greater 
than 11. The majority of studies had a representative 
cohort of patients with a specified comorbid condition 
(56 studies) and adjusted for potential confounders such 
as age and gender (41 studies).
short-term outcomes
Surgical complications
In this meta-analysis, 15 studies reported an OR for 
surgical complications in patients with comorbid condi-
tions (see figure 2). The risk of surgical complications 
was significantly higher in patients with cancer (pooled 
OR 1.33, 95% CI 1.09 to 1.62), diabetes (pooled OR 
1.12, 95% CI 1.01 to 1.25), kidney disease (pooled OR 
1.97, 95% CI 1.84 to 2.10) and stroke (pooled OR 1.40, 
95% CI 1.03 to 1.90). No studies reported surgical compli-
cations in patients with nervous system diseases or poor 
circulation.
Surgical site infections
Twenty-seven studies reported on surgical site infections 
after surgery. Overall, surgical site infections tended to 
occur more frequently in patients with comorbid condi-
tions but the likelihood was only significantly higher in 
patients with diabetes (pooled OR 1.90, 95% CI 1.32, 
2.74) and liver disease (pooled OR 2.46, 95% CI 1.46 to 
4.12) (see figure 2). No studies reported the likelihood of 
surgical site infections in patients with high blood pres-
sure, poor circulation or stroke.
Venous thromboembolism
Eighteen studies reported the risk of VTE postoperatively. 
VTE was more likely in patients with cancer (pooled OR 
2.30, 95% CI 1.35 to 3.92), depression (pooled OR 1.15, 
95% CI 1.02 to 1.30) and lung disease (pooled OR 1.29, 
95% CI 1.08 to 1.55). No studies reported the risk of VTE 
in patients with nervous system diseases, liver disease or 
poor circulation.
Readmissions to hospital
Sixteen studies looked at the presence of comorbid condi-
tions and being readmitted to hospital within 90 days after 
surgery. Overall, the likelihood of readmissions to hospital 
was significantly higher for patients with comorbid condi-
tions (8 out of 11) with the highest likelihood in patients 
with liver disease (pooled OR 1.79, 95% CI 1.36 to 2.35) (see 
figure 2). No studies reported the likelihood of readmis-
sions in patients with nervous system diseases or depression.
Figure 2 Forest plots of short-term outcomes.
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Short-term mortality
Thirteen studies looked at mortality within 90 days after 
surgery. Overall, the likelihood of short-term mortality 
tended to be significantly higher in patients with comorbid 
conditions (8 out of 11) with the highest likelihood in 
patients with heart disease (pooled OR 2.96, 95% CI 1.95 
to 4.48) (see figure 2). In contrast, one study reported 
a significant lower likelihood of short-term mortality in 
patients with depression (pooled OR 0.53, 95% CI 0.32 
to 0.88).
Long-term outcomes
Hip and knee function
Ten studies look at the impact of comorbid conditions on 
postoperative hip or knee function (see figure 3). Knee or 
hip function measures included: The Knee Society Knee 
Score,72 78 Western Ontario and McMaster Universities 
Osteoarthritis Index(WOMAC) Score,28 29 74 Oxford Knee 
Score35 and Activities of Daily Living limitation.83 87 95 The 
most frequently used measure was the WOMAC Score. 
Overall, the impact of comorbid conditions on function 
was variable. Patients with depression (pooled OR 1.69, 
95% CI 1.26 to 2.28), heart disease (pooled OR 1.24, 
95% CI 1.01 to 1.52) and stroke (pooled OR 1.32, 95% CI 
1.02 to 1.71) had worse function after surgery. Postopera-
tive function in patients with heart disease35 and stroke87 
was each only reported on by one study. No studies inves-
tigated the postoperative function in patients with cancer.
Health-related quality of life
Five studies compared the improvement in quality of life 
1 year after surgery in patients with comorbid conditions 
with those patients without comorbidities. Measures of 
quality of life included the Short Form-12,35 Short Form-
3629 74 96 and the Health Utilities Index.28 Overall, across 
comorbid conditions there was no consistent pattern. 
Quality of life was significantly worse for patients with 
heart disease (pooled OR 1.49, 95% CI 1.24 to 1.78) and 
lung disease (pooled OR 1.26, 95% CI 1.02 to 1.57). For 
patients with liver disease, quality of life was significantly 
better after surgery (pooled OR 0.36, 95% CI 0.20 to 
0.65).35 Postoperative quality of life in patients with heart 
disease and liver disease was each only reported by one 
study. No studies investigated the postoperative quality of 
life in patients with cancer or stroke.
Pain
Ten studies reported on the association between 
comorbid conditions and pain. Five (50%) studies looked 
at the outcome moderate to severe pain at 2 years and 
were studied by the same author.84 85 Other measures of 
pain included the WOMAC Pain Score28 and the Knee 
Figure 3 Forest plots of long-term outcomes.
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Society Pain Score.68 72 Overall, pain tended to be worse 
for patients with comorbid conditions but was not statisti-
cally significant. No studies investigated the postoperative 
pain in patients with cancer, nervous system diseases, liver 
disease or high blood pressure.
Revision surgery
Twelve studies reported on the likelihood of revision 
surgery in patients with comorbid conditions. Overall, 
revision surgery tended to be more likely in patients 
with comorbid conditions (6 out of 11) but the evidence 
remains weak. The pooled OR ranged from 1.11 (95% CI 
1.02 to 1.21) for patients with high blood pressure to 1.96 
(95% CI 1.16 to 3.30) for patients with liver disease. No 
studies reported the risk of revision surgery in patients 
with poor circulation or stroke.
Long-term mortality
Twelve studies reported the association between 
comorbid conditions and long-term mortality. Overall, 
the risk of long-term mortality tended to be higher for 
patients with comorbid conditions (7 out of 11). The 
pooled OR ranged from 1.38 (95% CI 1.05 to 1.80) 
for lung disease to 3.40 (95% CI 1.17 to 9.86) for liver 
disease (see figure 3). No studies investigated the risks of 
long-term mortality in patients with depression and poor 
circulation.
Impact of comorbid conditions
There is a lack of consistency across short-term and long-
term outcomes by different comorbid conditions. In 
the short term, comorbidities had the most impact on 
readmissions to hospital and short-term mortality, but 
the impact on surgical complications was variable with 
most results not statistically significant. In the long term, 
comorbid conditions had the most impact on risk of revi-
sion surgery and long-term mortality. The impact on func-
tion and quality of life was inconsistent across comorbid 
conditions. The evidence for the impact of comorbid 
conditions on long-term outcomes was weaker than for 
short-term outcomes. Heart disease of all the included 
comorbid conditions had the most impact on both 
short-term and long-term outcomes with an increased 
likelihood of readmissions, short-term mortality, worse 
function, worse quality of life, revision surgery and long-
term mortality.
Publication bias
We explored the possible impact of publication bias on 
outcomes: surgical complications, VTE, surgical site infec-
tions, readmissions, pain and mortality which had greater 
than six studies. This included studies in patients with 
diabetes (see figure 4) and kidney disease(see figure 5). 
The studies were not evenly distributed across both sides 
of the funnel plot. This asymmetry suggests that studies 
publishing negative effects may be missing. The impact of 
comorbidities on outcomes of hip and knee replacement 
may therefore be overestimated.
sensitivity analysis
We performed a sensitivity analysis to estimate the robust-
ness of the results by evaluating the effects of study quality 
(see online supplementary information 4). Overall, high-
quality studies pointed in the same direction as the lower-
quality studies, although the latter generally reported 
larger effects. Higher-quality studies did not include 
studies reporting on the outcomes function, quality of 
life and pain, which suggest the evidence on long-term 
outcomes is poor compared with the evidence of the 
impact of comorbid condition on short-term outcomes. 
This may be largely because of the smaller sample size 
of these studies, the lack of adjustment for confounders 
and the lack of patient-reported outcomes in joint regis-
tries which focus primarily on surgical complications, 
mortality and revision rates.
DIsCussIOn
Main findings
Overall, this meta-analysis demonstrates that patients with 
comorbid conditions are more likely to have a readmission 
and a higher short-term mortality in the early follow-up, 
but there is little evidence that patients benefit signifi-
cantly less in terms of health-related quality of life, func-
tion and pain compared with patients with no comorbid 
conditions. In the short term, the impact on surgical 
complications was variable and mostly statistically insignif-
icant. Patients with comorbid conditions tended to have 
a higher risk of revisions and long-term mortality but the 
available evidence was weak. There is some evidence of 
publication bias which may indicate an overestimation of 
the impact of comorbid conditions on outcomes. Given 
this, there is a need for high-quality studies in order to get 
a better understanding of the true impact of comorbidi-
ties on both short-term and long-term outcomes of hip 
and knee replacement.
Our study has implications for future research on clin-
ical indication for joint replacement surgery. Clinicians 
should take into account prognostic factors that affect 
treatment effectiveness in their decision-making to refer 
or select patients for hip or knee replacement97 but due 
to the lack of clarity on clinical indication for hip and 
knee replacement, they are not able to do so effectively.98 
Further research, specifically focusing on the long-term 
outcomes such as function, quality of life and pain and 
that stratify individual comorbidities according to severity 
are needed to provide clinicians with more evidence to 
guide their decision-making and management of patients 
with comorbid conditions and to minimise the variation 
and quality of care provided for this patient group.
Quality of evidence
Only 13% of the studies were graded as being of high 
quality. Poorer quality studies were typically less clear 
about the inclusion criteria for study patients and did not 
adjust for potential confounders such as age and gender. 
They were also based on either small single-site studies 
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or large administrative data-based studies that use data 
sources that were not from specialist arthroplasty data-
bases. Large administrative data-based studies greatly 
influenced the meta-analysis and thereby the limitations 
of these studies will therefore have a considerable influ-
ence on the validity of this meta-analysis. The higher 
quality studies primarily used joint registries and did not 
focus on patient-reported outcomes such as quality of life, 
function and pain.
Our sensitivity analysis showed that lower quality 
studies seem to overestimate the risk of short-term 
outcomes after hip and knee replacement in patients with 
comorbid conditions. Similarly, the evidence of reporting 
bias towards reporting positive findings may indicate an 
overestimation of the impact of comorbid conditions 
on outcomes of hip and knee replacement surgery. Due 
to the relatively small number of studies exploring the 
impact of each comorbid condition, it was not possible 
to fully explore the impact of publication bias and other 
factors that might cause heterogeneity.
It is important to consider, that patients included in 
the reported studies may represent a healthier popu-
lation. Several studies have shown that patients are not 
accessing hip and knee replacement because clinicians 
are excluding complex and severe patients who are 
deemed too high risk for surgery.99 This may introduce 
selection bias which may lead to an underestimation of 
the true effect on the impact of comorbid conditions on 
outcomes of hip and knee replacement surgery.
relation to prior reviews
Our study provides evidence that comorbid conditions 
have an impact on safety of the surgery but little impact 
on the effectiveness of the surgery in terms of quality of 
life, function and pain after hip and knee replacement 
surgery. There have been a number of earlier systematic 
reviews reporting the impact of comorbid conditions on 
outcomes after hip and knee replacement surgery. One 
systematic review and meta-analysis following elective 
total hip replacement in patients with diabetes found 
diabetes to be associated with a twofold increase risk of 
surgical site infections in line with our findings.16 Another 
one looking at the impact of comorbidity and length of 
stay and costs found limited evidence that comorbidities 
increase length of stay and costs compared with patients 
with no or fewer comorbidities.18 One systematic review 
looking at health-related quality of life in total hip and 
knee replacement reported that comorbid conditions 
was given as a reason for modest improvements in 
outcomes.17 This finding was only based on two studies 
Figure 4 Funnel plot showing 95% confidence limits for any surgical complications, surgical site infections, venous 
thromboembolism, readmissions to hospital and pain in patients with diabetes.
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both using composite comorbidity measures. Another 
systematic review looking at all preoperative predictors 
for outcomes for hip and knee replacement, however, 
demonstrated the inconsistency in study findings with 
seven studies reported a significant worse association 
between comorbid conditions and outcomes but six 
studies reported no significant association.14
LIMItAtIOns
For some combinations of outcomes and comorbid 
conditions, there were no studies of impact or impact was 
only based on a single study. Only six studies focused on 
patients with diseases of the nervous system whereas over 
half of the studies we reviewed investigated outcomes in 
patients with diabetes. Similarly, short-term outcomes, 
particularly surgical complications, were commonly 
investigated but only five studies28 29 35 74 96 reported on 
quality of life outcomes and the results on pain were 
from two publications.84 85 This highlights that evidence 
on short-term outcomes is stronger than evidence on 
long-term outcomes. Half of the studies were analyses of 
data collected in population-based administrative data-
sets. This may account for the relative scarcity of studies 
reporting on long-term outcomes such as quality of life or 
function that need patient-reported results.
We limited our review to studies with at least 100 patients 
and patients with the 11 comorbid conditions. Comorbid 
conditions that did not fit into the 11 categories that are 
captured in the PROMs programme for patients under-
going elective surgery in the English National Health 
Service were not included in this review. In addition, 
specific outcomes and patient-reported measures were 
not specified in the literature search so this may have 
resulted in the omission of some studies that met the 
inclusion criteria. We performed manual searches of rele-
vant journals however and checked the references lists 
of all included studies and other systematic reviews, so 
we believe that any missed studies would not affect our 
conclusions significantly.
The scope of this review required the grouping of 
heterogeneous studies. Across all studies, there were 
differences in study populations, definitions of comorbid 
conditions and their severity, definitions of outcomes, 
particularly for patient-reported outcomes, and the 
constructs they are measuring and the timing of their 
measurement. To make the results comparable and to be 
able to conduct any form of meta-analysis, some comorbid 
conditions were grouped together, outcomes were cate-
gorised as short and long term, and continuous outcomes 
were converted to OR using the Hasselblad and Hedges 
approach. In addition, it was not possible to evaluate hip 
Figure 5 Funnel plot showing 95% confidence limits for any surgical site infections, readmissions to hospital, short-term 
mortality and long-term mortality in patients with kidney disease.
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and knee replacement separately as 27 (38%) studies 
reported on combined hip and knee arthroplasties.
In addition to variation in definitions of comorbid 
conditions, few included studies graded comorbid condi-
tions according to severity which would have allowed 
a better understanding of their impact. For the few 
studies that reported results according to the severity of 
a comorbid condition, we included the most common 
severity subgroup, therefore excluding the most severe 
patients.
COnCLusIOn
Clinicians should be aware of the short-term risks relating 
to the safety of the surgery in their management of patients 
with comorbid conditions. There is little evidence that 
patients with comorbid conditions benefit significantly 
less from hip and knee replacement in terms of quality of 
life, function and pain after surgery than patients without 
comorbid conditions. As a result comorbid conditions 
have an impact on safety but little impact on effectiveness 
of hip and knee replacement surgery. Future research 
should however consider the severity of comorbid condi-
tions to better understand the impact of comorbid condi-
tions on outcomes.
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